Combining chemotherapy, immunotherapy, and targeted therapy for advanced cholangiocarcinoma
Official title: Chemotherapy Combined with Immunotherapy and Targeted Therapy in Advanced Intrahepatic Cholangiocarcinoma
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06718257 · Data updated 2026-11-12
This study is testing a new combination of chemotherapy, immunotherapy, and targeted therapy to see if it helps people with advanced cholangiocarcinoma feel better and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | March 31, 2025 |
| Study ends | May 31, 2025 |
| Registry record updated | February 6, 2025 |
| Trial ID | NCT06718257 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with histologically or radiologically confirmed advanced intrahepatic cholangiocarcinoma who have been treated with the specified chemotherapy and immunotherapy regimens.
✕Probably not a fit
Patients who have undergone direct surgery after hospitalization or received initial treatment involving local therapies or other comprehensive regimens may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to validate the efficacy and safety of a treatment regimen combining gemcitabine with cisplatin or oxaliplatin, along with PD-1/L1 inhibitors and TKI agents, in patients diagnosed with advanced cholangiocarcinoma. It is a multicenter, retrospective study that will collect and analyze clinical data from patients who have received these therapies as initial treatment. The goal is to gather comprehensive clinical information to guide future clinical practice in managing this condition.
Why it matters
Potential benefit: If successful, this approach could improve treatment outcomes for patients with advanced cholangiocarcinoma.
How similar studies have gone: While this approach combines established therapies, the specific combination and its efficacy in cholangiocarcinoma is being explored, indicating a novel aspect of treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or radiologically confirmed intrahepatic cholangiocarcinoma * Initially treated with GP/GEMOX or GP/GEMOX combined with PD-1/L1 and TKI inhibitors Exclusion Criteria: * Direct surgery after hospitalization * Initial treatment combined with local therapies (radiotherapy, radiofrequency, particle implantation, TACE, etc.) * Initial treatment involving other comprehensive therapeutic regimens
Where it's running
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Study coordinator: Weilin Wang, PHD
- Email: wam@zju.edu.cn
- Phone: +86 057187783820
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
68Ga-SorB PET/CT imaging for solid tumors
This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.
-
Breath test to help detect gastrointestinal cancers early
A breath test that looks for signals in exhaled air to see if someone with gut cancer symptoms might have oesophageal, stomach, pancreatic, liver, or colorectal cancer and need urgent testing.
-
Can an imaging tracer help predict if cholangiocarcinoma patients will respond to standard therapy
This study tests whether an imaging tracer called [18F]FTT used with PET/CT can predict how newly diagnosed cholangiocarcinoma patients will respond to the standard treatment of gemcitabine, cisplatin, and durvalumab.
-
Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.
-
KRAS G12V cancer patients get TCR1188-ABC cell therapy
This early-phase trial tests whether TCR1188-ABC cells can safely be given to adults with KRAS G12V-mutated metastatic cancers to see if it can help some types of pancreatic, biliary, colorectal, or lung cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.